Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Spruce Biosciences Inc (SPRB)

Spruce Biosciences Inc (SPRB)
0.4181 +0.0071 (+1.73%) 16:10 ET [NASDAQ]
0.4101 x 500 0.4155 x 1,900
Realtime by (Cboe BZX)
0.4101 x 500 0.4155 x 1,900
Realtime 0.4193 -0.0058 (-) 16:17 ET
Quote Overview for Thu, Feb 20th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.4108
Day High
0.4356
Open 0.4190
Previous Close 0.4110 0.4110
Volume 1,229,739 1,229,739
Avg Vol 355,582 355,582
Stochastic %K 81.40% 81.40%
Weighted Alpha -51.78 -51.78
5-Day Change +0.0141 (+3.44%) +0.0141 (+3.44%)
52-Week Range 0.3421 - 5.9500 0.3421 - 5.9500
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,976
  • Shares Outstanding, K 41,303
  • Annual Sales, $ 10,090 K
  • Annual Income, $ -47,920 K
  • EBIT $ -43 M
  • EBITDA $ -44 M
  • 60-Month Beta 2.37
  • Price/Sales 2.38
  • Price/Cash Flow N/A
  • Price/Book 0.33
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.94
  • Most Recent Earnings $-0.21 on 11/11/24
  • Next Earnings Date 03/12/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 97.91% ( -71.86%)
  • Historical Volatility 37.94%
  • IV Percentile 14%
  • IV Rank 6.38%
  • IV High 1,244.83% on 10/10/24
  • IV Low 19.73% on 06/17/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 46
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 2,267
  • Open Int (30-Day) 2,252

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.21
  • Number of Estimates 3
  • High Estimate -0.19
  • Low Estimate -0.23
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3562 +19.17%
on 01/29/25
Period Open: 0.3648
0.4356 -2.55%
on 02/20/25
+0.0597 (+16.37%)
since 01/17/25
3-Month
0.3421 +24.09%
on 01/13/25
Period Open: 0.4900
0.5740 -26.05%
on 11/29/24
-0.0655 (-13.37%)
since 11/20/24
52-Week
0.3421 +24.09%
on 01/13/25
Period Open: 5.2400
5.9500 -92.87%
on 03/08/24
-4.8155 (-91.90%)
since 02/20/24

Most Recent Stories

More News
S&P Futures Climb Ahead of Key U.S. PPI and Retail Sales Data, Adobe Earnings on Tap

March S&P 500 E-Mini futures (ESH24) are trending up +0.37% this morning as market participants geared up for crucial U.S. PPI and retail sales data while also awaiting quarterly results from software...

ESH24 : 5,101.67s (-1.01%)
DLTR : 76.29 (+0.89%)
TSLA : 354.40 (-1.71%)
INTC : 26.09 (+1.44%)
SKIN : 1.6000 (-5.33%)
ADBE : 454.69 (-0.50%)
DG : 76.13 (+0.66%)
ULTA : 366.68 (+1.87%)
DKS : 231.50 (+0.23%)
ECV.D.DX : 18.040 (+3.14%)
SDF.D.DX : 12.690 (-0.20%)
S : 22.78 (-1.39%)
S&P Futures Tick Higher as Investors Weigh Interest Rate Outlook

September S&P 500 futures (ESU23) are trending up +0.08% this morning after the S&P 500 and Nasdaq closed in the red on Thursday as technology stocks dropped on concerns over the outlook for Apple, while...

ESU23 : 4,491.72s (-0.32%)
AAPL : 245.83 (+0.39%)
SWKS : 67.32 (-0.44%)
QCOM : 173.70 (-0.87%)
AI : 29.90 (-2.83%)
INTC : 26.09 (+1.44%)
MCD : 303.05 (+0.37%)
CCC.LN : 2,198.000 (unch)
DOCU : 86.20 (-0.61%)
ADBE : 454.69 (-0.50%)
SMAR : 56.47 (+0.02%)
SWBI : 11.16 (+3.72%)
Spruce Biosciences to Present Findings on Retrospective Analysis of Completion Rates for CAH Studies at Pediatric Endocrine Society 2023 Annual Meeting

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.4251 (+3.43%)
Spruce Biosciences to Participate in May Investor Conferences

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.4251 (+3.43%)
Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.4251 (+3.43%)
Spruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.4251 (+3.43%)
Spruce Biosciences Announces $53.6 Million Private Placement Financing

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.4251 (+3.43%)
Spruce Biosciences to Participate in the SVB Securities Global Biopharma Conference

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.4251 (+3.43%)
Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.4251 (+3.43%)
Spruce Biosciences (NASDAQ: SPRB) Enters Into Collaboration with Kaken Pharmaceutical to Develop Tildacerfont for CAH in Japan

Spruce Biosciences, Inc. (NASDAQ: SPRB) is engaged as a late-stage biopharmaceutical company, which is focused on the research, development and

SPRB : 0.4251 (+3.43%)

Business Summary

Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy which are in clinical stage. Spruce Biosciences Inc. is based in Daly City, California.

See More

Key Turning Points

3rd Resistance Point 0.4459
2nd Resistance Point 0.4319
1st Resistance Point 0.4214
Last Price 0.4251
1st Support Level 0.3969
2nd Support Level 0.3829
3rd Support Level 0.3724

See More

52-Week High 5.9500
Fibonacci 61.8% 3.8078
Fibonacci 50% 3.1460
Fibonacci 38.2% 2.4843
Last Price 0.4251
52-Week Low 0.3421

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements